Home  »  Science   »  bluebird bio Inc. (NASDAQ:BLUE) Could Experience -...

bluebird bio Inc. (NASDAQ:BLUE) Could Experience -47.97% Growth

In last trading session, bluebird bio Inc. (NASDAQ:BLUE) saw 9.18 million shares changing hands with its beta currently measuring 1.09. Company’s recent per share price level of $6.17 trading at -$0.69 or -10.06% at ring of the bell on the day assigns it a market valuation of $532.16M. That closing price of BLUE’s stock is at a discount of -189.3% from its 52-week high price of $17.85 and is indicating a premium of 53.48% from its 52-week low price of $2.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 12.29 million shares which gives us an average trading volume of 8.72 million if we extend that period to 3-months.

bluebird bio Inc. (NASDAQ:BLUE) trade information

Upright in the red during last session for losing -10.06%, in the last five days BLUE remained trading in the red while hitting it’s week-highest on Thursday, 09/15/22 when the stock touched $6.17 price level, adding 13.95% to its value on the day. bluebird bio Inc.’s shares saw a change of -38.24% in year-to-date performance and have moved -12.23% in past 5-day. bluebird bio Inc. (NASDAQ:BLUE) showed a performance of 4.40% in past 30-days. Number of shares sold short was 13.41 million shares which calculate 1.16 days to cover the short interests.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

bluebird bio Inc. (BLUE) estimates and forecasts

Statistics highlight that bluebird bio Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 23.65% of value to its shares in past 6 months, showing an annual growth rate of 40.71% while that of industry is 1.70. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 65.40% in the current quarter and calculating 64.90% increase in the next quarter. This year revenue growth is estimated to rise 699.80% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $680k for the same. And 8 analysts are in estimates of company making revenue of $710k in the next quarter that will end on Sep 2022. Company posted $7.47 million and $37.6 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -90.90% while estimating it to be -98.10% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.90% during past 5 years. In 2022, company’s earnings growth rate is likely to be around 9.50% while estimates for its earnings growth in next 5 years are of 56.40%.

BLUE Dividends

bluebird bio Inc. is more likely to be releasing its next quarterly report between February 21 and February 25 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

bluebird bio Inc. (NASDAQ:BLUE)’s Major holders

Insiders are in possession of 1.19% of company’s total shares while institution are holding 72.84 percent of that, with stock having share float percentage of 73.72%. Investors also watch the number of corporate investors in a company very closely, which is 72.84% institutions for bluebird bio Inc. that are currently holding shares of the company. State Street Corporation is the top institutional holder at BLUE for having 13.15 million shares of worth $63.79 million. And as of Mar 30, 2022, it was holding 18.41% of the company’s outstanding shares.

The second largest institutional holder is Wellington Management Group, LLP, which was holding about 6.14 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 8.59% of outstanding shares, having a total worth of $29.78 million.

On the other hand, Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Apr 29, 2022, the former fund manager was holding 6.14 million shares of worth $22.29 million or 8.59% of the total outstanding shares. The later fund manager was in possession of 1.97 million shares on Mar 30, 2022, making its stake of worth around $9.56 million in the company or a holder of 2.76% of company’s stock.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]